Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Conference Call March 14, 2024 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Conference Call Participants Nazibur Rahman - Maxim Group James Molloy - Alliance Global Partners Dean Finley - Private Investor Operator Good day and welcome to the Quoin Pharmaceuticals Fourth Quarter Financial Results and Business Update Conference Call. All participants will be in listen-only mode. [Operato ...

Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical endpoints Eligibility age for enrollment into both studies has been lowered to fourteen years and older No safety concerns have been observed to date in either ongoing clinical study Quoin expect ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its chart ...

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Gordon Dunn – Chief Financial Officer Michael Myers – Chief Executive Officer Conference Call Participants James Molloy – Alliance Global Partners M Marin – Zacks Operator Good day, and welcome to the Quoin Pharmaceuticals Third Quarter Fiscal Results and Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, ...

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman - Maxim Group Laura Suriel - Alliance Global Partners Operator Good morning. Welcome to Quoin Pharmaceuticals, Ltd. Second Quarter Fiscal Results and Business Update Conference Call. All participants will be in a listen-only mode. [Operato ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) S ...

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman, Chief Executive Officer and Director Conference Call Participants Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Good morning and welcome to the Quoin Pharmaceuticals First Quarter Financial Results and Business Update Conference Call. All participants will be in a listen-only mode for the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37846 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) State of Israel 92- ...

Financial Data and Key Metrics Changes - As of December 31, 2022, cash and marketable securities were $12.9 million, down from $15.2 million as of September 30, 2022 [25] - The company reported a net loss of $2 million for Q4 2022 and $9.4 million for the full year [26] Business Line Data and Key Metrics Changes - Research and development expenses were $600,000 for Q4 2022 and $2.7 million for the year, primarily related to Netherton Syndrome clinical trials [26] - General and administrative expenses were $1.5 million in Q4 and $6.6 million for the year [26] Market Data and Key Metrics Changes - The company established 8 commercial partnerships covering 60 countries, indicating a broad market reach for its products [4] Company Strategy and Development Direction - Quoin intends to self-commercialize QRX003 and other pipeline products in the U.S. and Europe, aiming for a global launch [4] - The company is exploring M&A opportunities in the rare and orphan disease space, focusing on acquiring derisked late-stage assets [19][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cash position, which extends the financial runway into the second half of 2024, allowing for continued clinical development and potential M&A activities [19] - The company is optimistic about the progress of its clinical trials and anticipates presenting data in 2023 [27] Other Important Information - The company is working with regulatory consultants to explore conditional marketing approval for QRX003 in Europe, which could expedite commercialization [22] - Engagement with the Netherton community has been emphasized as critical for building awareness and support for the company's clinical programs [49] Q&A Session Summary Question: Expectations for patient recruitment in Phase III trial - Management indicated that recruitment is proceeding as expected and clinical data is anticipated to be available this year [29][30] Question: Percentage of severe Netherton Syndrome patients treated with off-label biologics - Management estimated that approximately 15% to 20% of severe Netherton patients are currently treated with off-label biologics, which are not reimbursed for this indication [35] Question: Breakdown of SG&A expenses - Management clarified that SG&A expenses appear high relative to R&D due to the timing of clinical studies and the compact nature of current trials [38][40]